Gass, Paul, Fasching, Peter A., Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Joerg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan W., Fersis, Nikos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kuehn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander ORCID: 0000-0003-2601-3398, Rauh, Claudia, Bayer, Christian M., Jacob, Adib, Schmidt, Katja, Belleville, Erik, Hadji, Peymann, Brucker, Sara Y., Beckmann, Matthias W., Wallwiener, Diethelm, Kuemmel, Sherko and Loehberg, Christian R. (2016). Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care, 11 (5). S. 315 - 323. BASEL: KARGER. ISSN 1661-3805

Full text not available from this repository.

Abstract

Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. Methods: Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. Results: In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. Conclusion: There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues. (C) 2016 S. Karger GmbH, Freiburg

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gass, PaulUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fasching, Peter A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fehm, TanjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Waal, JohannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rezai, MahdiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baier, BerndUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baake, GeroldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolberg, Hans-ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guggenberger, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warm, MathiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harbeck, NadiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuerstlein, RachelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Deuker, Joerg-UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dall, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richter, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wachsmann, GrischaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, CosimaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siebers, Jan W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fersis, NikosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuhn, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, ChristopherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vollert, Hans-WalterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Breitbach, Georg-PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Janni, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Landthaler, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kohls, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rezek, DanielaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Noesselt, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, GunnarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Henschen, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Praetz, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heyl, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuehn, ThorstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krauss, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomssen, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hohn, AndreUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tesch, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mundhenke, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hein, AlexanderUNSPECIFIEDorcid.org/0000-0003-2601-3398UNSPECIFIED
Rauh, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bayer, Christian M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jacob, AdibUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt, KatjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Belleville, ErikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hadji, PeymannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, Sara Y.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beckmann, Matthias W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wallwiener, DiethelmUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuemmel, SherkoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loehberg, Christian R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-288841
DOI: 10.1159/000452468
Journal or Publication Title: Breast Care
Volume: 11
Number: 5
Page Range: S. 315 - 323
Date: 2016
Publisher: KARGER
Place of Publication: BASEL
ISSN: 1661-3805
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
INTERNATIONAL EXPERT CONSENSUS; RECURRENCE SCORE ASSAY; PRIMARY THERAPY; RANDOMIZED-TRIAL; HIGHLIGHTS; WOMEN; TAMOXIFEN; STRATEGIES; IMPACT; VALIDATIONMultiple languages
Oncology; Obstetrics & GynecologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/28884

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item